Navigation Links
Pfizer Inc. and PAREXEL International Corp. Sign Strategic Partnership Agreement to Advance Clinical Development
Date:5/26/2011

nvolve a number of risks and uncertainties.  The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated restructuring charge of approximately $15 million over the fourth quarter of Fiscal Year 2011 as well as the first and second quarters of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2011 as filed with the SEC on May 10, 2011, which “Risk Factors” discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these for
'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Zacharon Pharmaceuticals Announces Research and Development Collaboration With Pfizer to Develop Drugs for Multiple Rare Disorders
2. Sutro Biopharma Forges Partnership with Pfizer for Discovery, Development and Commercialization of Novel Peptide-Based Therapeutics
3. Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety
4. Biovista Announces a Drug Repositioning Collaboration With Pfizer
5. MacroGenics Enters Global Research Collaboration and License Agreement with Pfizer
6. Pfizer, Merck, Roche/Genentech, GSK, J&J, BMS and More to Speak at Contracting & Outsourcing 2010
7. Pfizer Wins CIO 100 Award for Patient Enrollment Optimization Solution From DecisionView
8. Pfizer Announces EMPHASIS-HF Trial to Halt Recruitment due to Significant Benefit Observed in Patients Treated With Inspra® (Eplerenone)
9. Pfizer Animal Health Expands Global Commitment to a Safe Food Supply with a New Focus on Healthy Fish
10. Oramed Pharmaceuticals Announces That Dr. Michael Berelowitz, Senior Vice President at Pfizer, Joins its Board of Directors
11. Pfizer Global Manufacturing Announces Plans to Reconfigure Its Global Plant Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 Clintrax ... services located in Raleigh, NC ... Evans as Vice President of Administration. ... will oversee all corporate processes, including their alignment ... Clintrax Global, Brad worked as an HR executive, ...
(Date:8/20/2014)... often have it that American Indians largely were wiped ... influenza and tuberculosis brought to the New World by ... 20 million people lived in the Americas shortly before ... killed by European diseases., But new research led by ... Johannes Krause of the University of Tubingen in Germany ...
(Date:8/20/2014)... Neurotrope, Inc. (OTCQB: NTRP) today announced ... provide an update on Company activities. Access information:Date:Tuesday, ... 505-4369 (U.S. and Canada) or (719) 325-2315 Conference ... under "Investor Relations"The teleconference replay will be available ... 2014 at (888) 203-1112 (U.S. and ...
(Date:8/20/2014)... 2014  Decision Resources Group finds that the vascular access device ... , India and China ... equal to the size of the United States ... experience much faster growth as a result of strong economic expansion, ... key findings from Decision Resources Group,s coverage of the BRIC vascular ...
Breaking Biology Technology:Clintrax Global, Inc. Announces Addition to Executive Team 2Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3Neurotrope To Host Conference Call 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3
... Using bacteria to generate energy is a signifiant step ... University of East Anglia (UEA). Published today by ... Academy of Sciences (PNAS), the research demonstrates for ... proteins which enable bacterial cells to transfer electrical charge. ...
... 23, 2011 DATATRAK International, Inc. (OTCQX: DATA), a ... for the clinical trials industry, today announced the Company,s ... for the second consecutive year. "Being ... the hard work and dedication DATATRAK and its employees ...
... In the computer displays of medical equipment in hospitals ... major role. But a discovery reported from the University ... which have been found to change their ordering and ... low concentrations of a particular bacterial lipid, might find ...
Cached Biology Technology:Discovery opens the door to electricity from microbes 2DATATRAK Recognized as 2011 Crain's Leading EDGE Award Winner 2Liquid crystal droplets discovered to be exquisitely sensitive to an important bacterial lipid 2Liquid crystal droplets discovered to be exquisitely sensitive to an important bacterial lipid 3
(Date:8/20/2014)... Ore. -- When are athletes who have suffered concussions ... Oregon study has found that high school athletes who ... 60 days experience a significant regression in their abilities ... The regression, as seen in changes in their balance ... 19 athletes. Ten of the 12 had returned to ...
(Date:8/20/2014)... a burning spiciness that is irresistible to some, but ... are using their findings to develop a new drug ... caused by inflammation or other problems. They reported their ... clinical trials, in ACS, Journal of Medicinal Chemistry ... ago, scientists had pegged a compound called capsaicin as ...
(Date:8/20/2014)... chairs, synthetic rugs and plastic bags could one day ... rather than petroleum, scientists are now reporting. The novel ... the world deal with its agricultural and plastic waste ... , Athanassia Athanassiou, Ilker S. Bayer and colleagues at ... popularity is constantly growing. In 2012, its production reached ...
Breaking Biology News(10 mins):Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... Today,s opening of a new breast health center next ... significant research opportunities for the Translational Genomics Research Institute ... will include a tumor biorepository for TGen that will ... to diagnose and treat breast cancer, which affects 1 ...
... the results are receiving rave reviews from apple lovers. ... a new apple cultivar has been introduced by scientists ... New Jersey, and Indiana experiment stations. This high-quality dessert ... S. Korban, of the Department of Natural Resources and ...
... GREECETo grow the high-quality potted plants preferred by ... affect plant growth and development. The use of ... production of compact gardenia plants; the chemicals are ... the production of lateral shoots that create aesthetically ...
Cached Biology News:Breast health center gives TGen new research opportunities 2Apple enthusiasts welcome WineCrisp 2Photoselective film proves effective for controlling height in potted gardenia plants 2
Mouse monoclonal [BC-4] to Aggrecan xxPEN ( Abpromise for all tested applications). entrezGeneID: 176 SwissProtID: P16112...
Mouse monoclonal [1.F.1] to Yersinia pestis F1 antigen ( Abpromise for all tested applications). Antigen: Purified F1 antigen of Y. pestis vaccine strain EB....
7G10 anti-Fasciclin III...
Rabbit polyclonal to Nck alpha ( Abpromise for all tested applications). entrezGeneID: 4690 SwissProtID: P16333...
Biology Products: